BridgeBio Pharma, Inc. (BBIO) Discusses Achondroplasia Pathophysiology, Unmet Wants, and PROPEL 3 Infigratinib Part 3 Examine January 9, 2026 8:00 AM EST
Firm Contributors
Justin To
Daniela Rogoff
Convention Name Contributors
Janet Legare
Salim Syed – Mizuho Securities USA LLC, Analysis Division
Biren Amin – Piper Sandler & Co., Analysis Division
Tyler Van Buren – TD Cowen, Analysis Division
Lin Tsai – Jefferies LLC, Analysis Division
Mani Foroohar – Leerink Companions LLC, Analysis Division
Danielle Brill Bongero – Truist Securities, Inc., Analysis Division
Presentation
Operator
Thanks for standing by. At the moment, I wish to welcome everybody to the BridgeBio Pharma Achondroplasia Investor Webinar. [Operator Instructions]
I might now like to show the decision over to Justin To. It’s possible you’ll start.
Justin To
Good morning, and welcome to the BridgeBio webcast for the infigratinib program for achondroplasia. Earlier than we start at present, I would prefer to remind our viewers that we’ll be making forward-looking statements at present. For a dialogue of those dangers, please see BridgeBio’s most up-to-date monetary statements. That is an thrilling time for a program as we’ve got lately achieved final participant’s final go to for PROPEL 3, our Part III medical trial in achondroplasia, and we anticipate to announce high line outcomes by the tip of the primary quarter.
In the present day, we’re excited to be joined by Dr. Janet Legare, Professor in Genetics within the Division of Pediatrics on the College of Wisconsin College of Medication and Public Well being. She can be an investigator within the PROPEL 3 trial, and she or he is the Director of the Midwest Regional Bone Dysplasia Clinic, one of many largest of its variety in the USA. She shall be offering an summary of achondroplasia, its genetic pathophysiology and unmet medical want.
We are going to then have Dr. Daniela Rogoff, who’s the Chief Medical Officer of Skeletal Dysplasias
